This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Previously Presented): A process for producing a compound of formula I:



I

wherein

R_1 is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl, and

R_2 is CO-C_{1-6} alkyl, CO-C_{6-12} aryl, CO-C_{1-6} alkoxy, CO-C_{6-12} aryloxy, or CO-C_{6-12} arylalkyl;

said process comprising:

a) subjecting a compound of formula II:



II

to an enzymatic diastereomeric resolution in the presence of a suitable amount of Pig Liver Esterase enzyme or Porcine Pancreatic Lipase enzyme;

b) recovering said compound of formula I.

2. (Original): The process according to claim 1, wherein R_1 is C_{1-12} alkyl.

3. (Previously Presented): The process according to claim 1 wherein R_2 is CO-C_{1-6} alkyl.

4. (Previously Presented): The process according to claim 1, wherein R_2 is CO-C_{6-12} aryl.

5. (Previously Presented): The process according to claim 1, wherein the enzyme is Pig Liver Esterase.

6. (Previously Presented): The process according to claim 1, wherein the enzyme is Porcine Pancreatic Lipase.

7. (Previously Presented): The process according to claim 1, further comprising:

a) replacing the functional group at position C4 of the compound of formula I to produce a compound of formula V:



V

wherein B is purine or pyrimidine base or an analogue thereof;

b) removing the group R_2 of said compound of formula V; and

c) recovering a compound of formula VI:



VI

or a pharmaceutically acceptable salt thereof.

8. (Previously Presented): The process according to claim 7, wherein B is:



;


;


or


;

R_3 is H, C_{1-6} alkyl, C_{1-6} acyl, or CO-R_9;

R_9 is H or C_{1-6} alkyl;

R_4 and R_5 are each independently H, C_{1-6} alkyl, bromide, chloride, fluoride, iodide or CF_3; and

R_6, R_7 and R_8 are each independently H, bromide, chloride, fluoride, iodide, amino, hydroxyl, or C_{3-6} cycloalkylamino.

9. (Previously Presented): The process according to claim 1, further comprising the step of recovering a compound of formula VII:



VII

10. (Original): A process according to claim 1, wherein R_1 is C_{1-12} alkyl and R_2 is CO-C_{6-12} aryl.

11. (Original): A process according to claim 1, wherein R_1 is methyl and R_2 is benzoyl.

12. (Currently Amended): A process for producing a compound of formula III:



III

wherein

R_{11} is C_{1-12} alkyl, C_{2-12} alkenyl, C_{2-12} alkynyl, C_{6-12} aryl, C_{3-10} heterocycle, C_{6-12} aralkyl or C_{3-10} heteroaralkyl; and

R_{12} is CO-C_{1-6} alkyl, CO-C_{6-12} aryl, CO-C_{1-6} alkoxy, CO-C_{6-12} aryloxy, or CO-C_{6-12} arylalkyl,

said process comprising:

a) subjecting a compound of formula IV:



IV

to an enzymatic diastereomeric resolution in the presence of a suitable amount of an enzyme, wherein said enzyme is Candida Antarctica "A" lipase, Candida Antarctica "B" lipase, Candida Lypolitica Lipase, or Rhizomucor Miehei Lipase; and

b) recovering said compound of formula III.

13. (Original): The process according to claim 12, wherein R_{11} is C_{1-12} alkyl.

14. (Previously Presented): The process according to claim 12, wherein R_{12} is CO-C_{1-6} alkyl.

15. (Original): The process according to claim 12, wherein R_{12} is CO-C_{6-12} aryl.

16. (Original): The process according to claim 12, wherein the enzyme is Candida Antarctica "A" lipase.

17. (Original): The process according to claim 12, wherein the enzyme is Candida Antarctica "B" lipase.

18. (Original): The process according to claim 12, wherein the enzyme is Candida Lypolitica Lipase.

19. (Original): The process according to claim 12, wherein the enzyme is Rhizomucor Miehei Lipase.

20. (Previously Presented): The process according to claim 12, further comprising:

a) replacing the functional group at position C4 of the compound of formula III to produce a compound of formula VIII:



VIII

wherein B is purine or pyrimidine base or an analogue thereof;

b) removing group R_{12} of said compound of formula VIII;

c) recovering a compound of formula IX:



IX

or a pharmaceutically acceptable salt thereof.

21. (Previously Presented): The process according to claim 20, wherein B is



R_3 is H, C_{1-6} alkyl, C_{1-6} acyl and CO-R_9;

R_9 is H or C_{1-6} alkyl;

R_4 and R_5 are each independently H, C_{1-6} alkyl, bromide, chloride, fluoride, iodide or CF_3; and R_6, R_7 and R_8 are each independently H, bromide, chloride, fluoride, iodide, amino, hydroxyl or C_{3-6} cycloalkylamino.

22. (Previously Presented): The process according to claim 20, further comprising converting said compound of formula III to a compound of formula IV and recovering said compound of formula X:



X

23. (Original): A process according to claim 12, wherein R_{11} is C_{1-12} alkyl and R_{12} is CO-C_{6-12} aryl.

24. (Original): A process according to claim 12, wherein R_{11} is methyl and R_{12} is benzoyl.

25. (New): A process according to claim 1, wherein said process is carried out at a pH of 6 to 8, at a temperature in the range of 5 to 50°C, and in the presence of a solvent, and the concentration of enzyme with respect to the solvent is 1 mg/ml to 100 mg/ml.

26. (New): A process according to claim 1, wherein said process is carried out at a pH of 6 to 8, at a temperature in the range of 5 to 50°C, and in the presence of a solvent, and the concentration of enzyme with respect to the solvent is 1 mg/ml to 100 mg/ml.

27. (New): A process according to claim 1, wherein the weight ratio of the amount of enzyme to the amount of the compound of formula II is 1% to 25%.

28. (New): A process according to claim 1, wherein the weight ratio of the amount of enzyme to the amount of the compound of formula II is 5% to 10%.

29. (New): A process according to claim 12, wherein the weight ratio of the amount of enzyme to the amount of the compound of formula IV is 1% to 25%.

30. (New): A process according to claim 12, wherein the weight ratio of the amount of enzyme to the amount of the compound of formula IV is 5% to 10%.